Roundup: Nanexa, Earendil Labs, and Atavistik Bio enter platform deals with Novo Nordisk, Genentech, and Roche. Three platform-technology deals paired Nanexa, Earendil Labs, and Atavistik Bio with Novo Nordisk, Genentech, and Roche to advance next-generation metabolic and oncology medicines. Platform-technology deals dominated this week's dealmaking, as drug delivery and discovery specialists licensed their proprietary systems to larger partners chasing next-generation metabolic and oncology medicines. Nanexa licenses Pharmashell platform to Novo Nordisk. Nanexa AB entered into a global exclusive license and collaboration agreement with Novo Nordisk for the use of the Pharmashell technology platform for certain peptide-based drugs targeting obesity, type 2 diabetes, and other cardiometabolic indications. As part fo the deal, Nanexa is eligible to receive total payments upwards of $1.33 billion, including $701 million in upfront payment and development and regulatory milestones, with the remaining milestone payments tied to sales.[1] Nanexa is also eligible to receive low single-digit royalties on global net sales of products developed under the agreement.[1] Under terms of the agreement, Novo is expected to receive a global license to use Nanexa's Pharmashell technology platform in up to five development programs.[1] The collaboration includes development of long-acting injectable formulations with different administration-frequency profiles, with monthly and quarterly administration as target profiles. Pharmashell is Nanexa's proprietary atomic layer deposition-based drug delivery platform, designed to enable controlled and sustained release of active pharmaceutical ingredients through an ultra-thin inorganic coating applied to individual drug particles, intended to support differentiated long-acting injectable drugs that reduce dosing frequency and improve the treatment experience for people living with chronic metabolic or cardiovascular disease.[1] "We are very excited about and proud of this license agreement with Novo and look forward to working with them to successfully develop products with less frequent dosing in obesity and type 2 diabetes indications. Following our license and option agreement with Moderna in 2025, this agreement further strengthens the external validation of Pharmashell as a broadly applicable drug delivery platform and we believe this provides a strong foundation for expanding Pharmashell into additional therapeutic areas and to selectively advance additional internal programs towards clinical proof of concept, allowing us to capture greater value from the breadth of the Pharmashell platform," said David Westberg, CEO of Nanexa. Earendil Labs partners with Genentech. Earendil Labs announced a research collaboration with Genentech, a member of the Roche Group, to discover and develop multiple therapeutic bispecific antibody programs in oncology. Earendil Labs will receive a $55 million upfront payment, and the total potential value of the collaboration, including upfront, development, regulatory and sales milestone payments is expected to excess $1.5 billion.[2] Earendil Labs is also eligible to receive tiered royalties on net product sales. Under the collaboration, Earendil Labs will lead antibody discovery and research through the early clinical development stage for antibody programs directed to certain pre-agreed target combinations, while Genentech will assume responsibility for subsequent global clinical development and commercialization of antibody programs arising from the collaboration.[2] "Genentech is a pioneer in defining modern biologics cancer medicine. Earendil Labs is building an AI-driven high-throughput biology platform that effectively integrates AI directly into biologics research and development - from predictive protein modeling and generative protein design to rapid experimental validation. By combining our platform with Genentech's deep expertise in oncology drug development, we aim to accelerate the creation of differentiated bispecific antibodies and translate them into new medicines," said Jian Peng, PhD, CEO of Earendil Labs. Atavistik Bio strikes CVRM discovery collaboration with Roche. Atavistik Bio entered into a strategic research collaboration with Roche to discover and develop novel small molecule therapeutics against multiple targets for cardiovascular, renal, and metabolic diseases. As part of the deal, Atavistik Bio is set to receive an upfront payment of $70 million and may be eligible to receive additional research, development, and commercial milestone payments of up to $1.9 billion, along with tiered royalties on future net sales of any approved medicines resulting from the collaboration.[3] The collaboration will leverage Atavistik Bio's proprietary Amps drug discovery platform and expertise in allosteric drug discovery to identify novel functional binding pockets and advance selective small molecule therapeutics against targets for cardiovascular, renal, and metabolic disease.[3] By uncovering cryptic, biologically relevant binding pockets, Atavistik Bio's platform enables new approaches to develop differentiated small molecules against therapeutically important targets that have historically been challenging to modulate. Under the terms of the agreement, Atavistik Bio will be responsible for discovery and research activities for the collaboration targets, with Roche responsible for further preclinical and clinical development, regulatory, and commercialization activities.[3] "We are pleased to partner with Roche, whose deep expertise in drug development makes them an ideal partner to extend the reach of our allosteric discovery platform," said Bryan Stuart, chief executive officer of Atavistik Bio. "This collaboration reflects the strength and broad applicability of our platform across therapeutic areas, further validating our approach to allosteric drug discovery. We are excited to extend the application of our platform into CVRM diseases by leveraging Roche's deep expertise in the field, while we remain focused internally on advancing a robust pipeline of potentially best-in-class therapies for patients with rare hematologic diseases."

Atavistik Bio announces strategic research collaboration with Roche to discover and develop novel allosteric therapeutics. * Collaboration leverages Atavistik Bio's proprietary AMPS(TM) platform to identify and advance novel allosteric small molecules against multiple targets for cardiometabolic diseases * Atavistik Bio to receive $70 million upfront with potential milestone payments up to $1.9B plus tiered royalties CAMBRIDGE, Mass., Sept. 24, 2026 (GLOBE NEWSWIRE) - Atavistik Bio, a clinical-stage biotechnology company advancing a pipeline of hematology therapeutics developed through a novel allosteric discovery platform, today announced that it has entered into a strategic research collaboration with Roche to discover and develop novel small molecule therapeutics against multiple targets for cardiovascular, renal, and metabolic (CVRM) diseases. The collaboration will leverage Atavistik Bio's proprietary AMPS(TM) drug discovery platform and expertise in allosteric drug discovery to identify novel functional binding pockets and advance selective small molecule therapeutics against targets for CVRM diseases. By uncovering cryptic, biologically relevant binding pockets, Atavistik Bio's platform enables new approaches to develop differentiated small molecules against therapeutically important targets that have historically been challenging to modulate. "We are pleased to partner with Roche, whose deep expertise in drug development makes them an ideal partner to extend the reach of our allosteric discovery platform," said Bryan Stuart, Chief Executive Officer of Atavistik Bio. "This collaboration reflects the strength and broad applicability of our platform across therapeutic areas, further validating our approach to allosteric drug discovery. We are excited to extend the application of our platform into CVRM diseases by leveraging Roche's deep expertise in the field, while we remain focused internally on advancing a robust pipeline of potentially best-in-class therapies for patients with rare hematologic diseases." Atavistik Bio will receive an upfront payment of $70 million and may be eligible to receive additional research, development, and commercial milestone payments of up to $1.9 billion, and tiered royalties on future net sales of any approved medicines resulting from the collaboration. Under the terms of the agreement, Atavistik Bio will be responsible for discovery and research activities for the collaboration targets, with Roche responsible for further preclinical and clinical development, regulatory, and commercialization activities. "Treating CVRM diseases remains a core strategic priority for Roche. By pairing Atavistik Bio's novel approach to discovering allosteric small molecules with our expertise in disease biology and drug development, we aim to translate complex science into transformative, oral small-molecule therapeutics for patients who need them most" said Boris L. Zaïtra, Head of Corporate Business Development at Roche. About Atavistik Bio Atavistik Bio is a clinical stage biotechnology company advancing a pipeline of hematology therapeutics developed through a novel allosteric discovery approach. Atavistik Bio is advancing multiple programs with best-in-class potential, including the lead asset, ATV-1601, an investigational oral allosteric AKT1-selective inhibitor for the treatment of Hereditary Hemorrhagic Telangiectasia (HHT) and advancing a JAK2[V617F] mutant-selective inhibitor program for myeloproliferative neoplasms. Atavistik Bio is led by an experienced team of drug hunters with a proven track record of developing marketed therapies and backed by top-tier investors, including The Column Group, Nextech Invest, Lux Capital, Regeneron Ventures, and RA Capital Management. To learn more, visit us at atavistikbio.com and follow us on LinkedIn. Investor Contact:

Roche signs drug-discovery deal with Atavistik Bio worth up to $2 billion. By Thomson Reuters Sep 24, 2026 | 8:01 AM Sept 24 (Reuters) - Drug developer Atavistik Bio said on Thursday it has signed a deal with Swiss drugmaker Roche potentially worth nearly $2 billion, including milestone payments, to develop oral treatments for cardiovascular, kidney and metabolic diseases. Here are some details: - As part of the agreement, Atavistik will receive $70 million upfront and could get up to $1.9 billion in research, development and commercial milestone payments, plus royalties on sales of approved drugs, the privately held drug developer said. - The partnership covers multiple drug targets and will use Atavistik's proprietary technology to find hidden pockets on disease-causing proteins, potentially allowing drugs to be developed against targets conventional methods have struggled to reach. - Unlike many traditional drugs that bind to a protein's main active site, Atavistik's approach targets other sites that regulate how the protein works, which could allow for more selective treatments with fewer unintended effects. - Atavistik will lead early discovery and research, while Roche will handle further lab and human testing, regulatory filings and commercialization, Atavistik said. - Atavistik will continue developing its own treatments for rare blood disorders, including for hereditary hemorrhagic telangiectasia, which causes malformed blood vessels. - The companies did not disclose the number of targets covered by the partnership or provide development timelines. (Reporting by Kunal Das in Bengaluru; Editing by Pooja Desai)